Developer docs
API playgroundTry for free, no card

Search company profiles

Japan Biotechno Pharma

Full company profile

uuid002ceom

Namestring
Japan Biotechno Pharma
Legal namestring
日本バイオテクノファーマ株式会社 (Japan Biotechno Pharma Co., Ltd.)
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Japan Biotechno Pharma Co., Ltd. (日本バイオテクノファーマ株式会社) is a privately-held Japanese pharmaceutical and medical device company headquartered in Chuo-ku, Tokyo, operating with 11–50 employees across three integrated business lines: pharmaceutical products (including Tepoxxx Capsule 200mg/Tecovirimat — Japan's first approved treatment for smallpox, mpox, cowpox, and vaccinia complications — alongside antibody drugs and vaccines/globulins); medical devices and consumer health products (surgical instruments, infection-prevention eyewear such as Shield Frame, the WellisAir air purification system validated against influenza A H3N2, and face shields); and in vitro diagnostics plus animal health (J-Bio Rapid PCR Kit SARS-CoV-2, COVID-19 antibody/antigen kits, iSWAB Microbiome EL specimen tubes, the WITHaPET AI digital stethoscope, and the PIPPO pet urine test kit). The company holds Class 1 pharmaceutical manufacturing/sales, Class 1 medical device, in vitro diagnostic, and advanced medical device sales permits issued by Japanese regulators between 2017 and 2020, and has received AMED grants for emerging/re-emerging infectious disease drug development in consecutive fiscal years. Revenue is generated through a hybrid model: direct B2B sales of pharmaceuticals, IVDs, and medical devices to healthcare institutions; a multi-brand direct-to-consumer e-commerce footprint via the Well-Being OnlineShop and sub-brand storefronts (WellisAir, WithaPet, Pippo); and physical distribution through its newly established Korea (August 2024) and Vietnam (May 2025) branches, primarily serving healthcare professionals, medical institutions, veterinary clinics, pet owners, and consumer wellness buyers across Japan, South Korea, and Vietnam.

Short descriptiontext

Japan Biotechno Pharma is a Tokyo-based pharmaceutical and medical device company manufacturing antivirals, in vitro diagnostics, and animal health products, serving healthcare institutions, veterinary clinics, and consumers across Japan, Korea, and Vietnam.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTokyo, Japan
HQ citystring
Tokyo
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, biopharmaceutical development, medical device manufacturing, in vitro diagnostics, veterinary medical devices
Industry3 codes
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
SECONDARYHLAMAFAI
Laboratory & Point-of-Care Diagnostic Devices (Analyzers, Test Kits, Microscopy)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Medical Devices & Supplies
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Surgical and Medical Instrument Manufacturing339112
SIC code4 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
Product category
Pharmaceuticals and Medical Devices
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Pharmaceutical Products
TypeOne Time License
Description

Revenue from antiviral drugs, antibody pharmaceuticals, vaccines/globulins, and approved treatments including Tepoxxx Capsule for poxviruses

japanbiotechnopharma.com
2Medical Devices
TypeHardware Sales
Description

Surgical instruments, infection prevention glasses (face shields), and related medical equipment

japanbiotechnopharma.com
3In Vitro Diagnostics
TypeOne Time License
Description

J-Bio rapid PCR kits and other diagnostic pharmaceutical products

japanbiotechnopharma.com
4Animal Health Products
TypeHardware Sales
Description

AI digital stethoscopes, pet urine test kits, and animal health monitoring devices

japanbiotechnopharma.com
5Well-Being Consumer Products
TypeHardware Sales
Description

WellisAir air purification systems and consumer wellness products sold through online shop

japanbiotechnopharma.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1WellisAir
Description

Air purification system for sterilization and air quality improvement.

japanbiotechnopharma.com
+4 more records
Core offering1 text field

Japan Biotechno Pharma manufactures and distributes pharmaceutical products (antiviral drugs including Japan's first approved Tecovirimat treatment for poxvirus complications, antibody drugs, vaccines, and globulins), medical devices (surgical instruments, infection protection eyewear, face shields, and the WellisAir air purification system), in vitro diagnostics (J-Bio Rapid PCR Kit for SARS-CoV-2, COVID-19 antibody/antigen test kits), and animal health products (AI-powered digital stethoscope and pet urine test kits). The company serves medical professionals, healthcare institutions, veterinary clinics, and individual consumers through its own e-commerce storefront and direct sales.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Japan's first approved poxvirus treatment (Tepoxxx Capsule 200mg) - approved January 7, 2025
+2 more records
Product overview1 text field

Japan Biotechno Pharma operates as a diversified pharmaceutical and medical technology company with three main business segments: (1) Pharmaceutical Business covering antiviral drugs (Tepoxxx Capsule 200mg/Tecovirimat - Japan's first treatment for poxvirus complications), antibody drugs, and vaccines/globulins; (2) Medical Device Business including surgical instruments, infection control products (Shield Frame glasses, face shields), and WellisAir air purification system proven effective against influenza A virus and coronavirus; and (3) In Vitro Diagnostics and Animal Health Products including J-Bio Rapid PCR Kit for SARS-CoV-2, COVID-19 antibody/antigen test kits, iSWAB microbiome specimen collection tubes, AI-powered WITHaPET digital stethoscope, and PIPPO pet urine test kit. The portfolio spans human and veterinary applications with both pharmaceutical and medical device products.

Product and service13 records
1Tepoxxx Capsule 200mg (Tecovirimat)
CategoryAntiviral Pharmaceuticals
Description

Antiviral capsule drug containing Tecovirimat 200mg, indicated for treatment of poxvirus infections including smallpox, mpox, cowpox, and post-vaccination complications. Approved as Japan's first such treatment for healthcare professionals and medical institutions.

2WellisAir Air Purification System
CategoryMedical Devices / Consumer Wellness
Description

Air sterilization and purification device confirmed to reduce infectivity of influenza A virus (H3N2) and coronavirus. Sold to consumers and businesses seeking infection prevention through air quality control.

3WITHaPET Digital Stethoscope
CategoryVeterinary Medical Devices
Description

AI-powered digital stethoscope designed for veterinary professionals and pet owners to monitor pet health through digital auscultation.

4PIPPO Pet Urine Test Kit
CategoryVeterinary Diagnostics
Description

At-home urine testing kit for pets, enabling pet owners to perform preliminary health screening for their animals.

5J-Bio Rapid PCR Kit SARS-CoV-2
CategoryIn Vitro Diagnostics
Description

In vitro diagnostic reagent enabling rapid PCR detection of SARS-CoV-2 for clinical laboratories and healthcare facilities, with regulatory approval (approval number 30300EZX00073000).

6COVID-19 Antibody Test Kit (IgM/IgG)
CategoryIn Vitro Diagnostics
Description

Rapid detection test kit for IgM and IgG antibodies to SARS-CoV-2, designed for healthcare professionals and diagnostic use to assess immune response following infection.

7COVID-19 Antigen Test Kit
CategoryIn Vitro Diagnostics
Description

Antigen detection test kit for identifying active SARS-CoV-2 infection, validated for the Omicron variant, sold as 2-test individual packaging.

8Shield Frame Infection Protection Glasses
CategoryMedical Devices
Description

Droplet protection eyewear developed for medical professionals to prevent infection during clinical work.

9Face Shield
CategoryMedical Devices
Description

Japanese-made face shield for droplet prevention, emphasizing comfort and performance for infection control in medical and workplace settings.

10iSWAB Microbiome EL
CategoryIn Vitro Diagnostics
Description

Specimen collection and transport tube enabling RNA extraction in 5 minutes for microbiome analysis, used by research and clinical laboratories.

11Antibody Drugs
CategoryBiopharmaceuticals
Description

Biopharmaceutical antibody drugs for therapeutic applications, developed and distributed for healthcare institutions.

12Vaccines and Globulins
CategoryBiopharmaceuticals
Description

Vaccine and immunoglobulin (globulin) products for immunization and passive immunity, distributed to medical institutions and healthcare providers.

13Surgical Instruments and Equipment
CategoryMedical Devices
Description

Medical devices and surgical instruments for healthcare facilities, distributed under the company's Class 1 medical device manufacturing and sales license.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Japan Agency for Medical Research and Development (AMED)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-02-01
Description

Japan Biotechno Pharma was selected for AMED's programs for emerging and re-emerging infectious disease drug development in both Reiwa 3 (2021) and Reiwa 4 (2022) fiscal years, receiving government support for innovative pharmaceutical development targeting infectious diseases.

japanbiotechnopharma.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Chimerix develops antivirals targeting poxviruses and other infectious diseases. Comparable to Japan Biotechno Pharma as a small-cap antiviral developer with regulatory expertise in the same disease space as Tepoxxx.

TypeBroad incumbent
Description

FUJIFILM's healthcare segment includes pharmaceuticals, medical devices, and IVD reagents. Comparable as a diversified Japanese healthcare conglomerate with overlapping product categories across therapeutics, devices, and diagnostics.

TypeBroad incumbent
Description

Denka is a Japanese chemical and specialty manufacturer with a healthcare segment that includes in vitro diagnostics and infection prevention products. Comparable as a Japanese company with overlapping diagnostic and medical device offerings.

4AnGes MG
TypeEmerging player
Description

AnGes is a Japanese biotech focused on DNA vaccines and genetic medicines, with COVID-19 vaccine development history. Comparable as a small-cap Japanese biopharmaceutical with infectious disease R&D focus and government grant funding experience.

5H.U. Group Holdings (formerly SRL)
TypeBroad incumbent
Description

H.U. Group operates clinical laboratory testing services and IVD products in Japan. Comparable as a Japanese diagnostics player with relevant IVD distribution and laboratory services overlap.

TypeBroad incumbent
Description

Sysmex is a leading Japanese in vitro diagnostics company with global reach. Comparable as a Japan-based IVD player, though much larger; useful for IVD regulatory and commercial benchmarking relevant to J-Bio PCR Kit.

TypeBroad incumbent
Description

Shionogi is a Japanese pharmaceutical company with a strong infectious disease and antiviral portfolio (including COVID-19 therapeutics). Comparable as a Japan-based pharma with regulatory expertise and government relationships in infectious disease drug development.

TypeDirect peer
Description

Bavarian Nordic develops vaccines and therapeutics against poxviruses including mpox/smallpox (JYNNEOS vaccine). Comparable as a player in the broader poxvirus preparedness ecosystem, often used alongside Tecovirimat treatment.

TypeDirect peer
Description

SIGA Technologies is the originator of Tecovirimat (TPOXX), the same active ingredient Japan Biotechno Pharma now sells in Japan under the Tepoxxx brand. Both companies operate in the poxvirus antiviral space and pursue government stockpiling channels.

10KM Biologics
TypeBroad incumbent
Description

KM Biologics is a Japanese vaccine and biologics manufacturer owned by Meiji Holdings. Comparable as a domestic Japanese player with biopharmaceutical manufacturing capabilities, vaccine portfolio, and regulatory licenses aligned with Japan Biotechno Pharma's pharmaceutical business.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Japan Biotechno Pharma

Pharmaceuticals and Medical Devicesjapanbiotechnopharma.com

Japan Biotechno Pharma is a Tokyo-based pharmaceutical and medical device company manufacturing antivirals, in vitro diagnostics, and animal health products, serving healthcare institutions, veterinary clinics, and consumers across Japan, Korea, and Vietnam.

What Japan Biotechno Pharma does

Japan Biotechno Pharma Co., Ltd. (日本バイオテクノファーマ株式会社) is a privately-held Japanese pharmaceutical and medical device company headquartered in Chuo-ku, Tokyo, operating with 11–50 employees across three integrated business lines: pharmaceutical products (including Tepoxxx Capsule 200mg/Tecovirimat — Japan's first approved treatment for smallpox, mpox, cowpox, and vaccinia complications — alongside antibody drugs and vaccines/globulins); medical devices and consumer health products (surgical instruments, infection-prevention eyewear such as Shield Frame, the WellisAir air purification system validated against influenza A H3N2, and face shields); and in vitro diagnostics plus animal health (J-Bio Rapid PCR Kit SARS-CoV-2, COVID-19 antibody/antigen kits, iSWAB Microbiome EL specimen tubes, the WITHaPET AI digital stethoscope, and the PIPPO pet urine test kit). The company holds Class 1 pharmaceutical manufacturing/sales, Class 1 medical device, in vitro diagnostic, and advanced medical device sales permits issued by Japanese regulators between 2017 and 2020, and has received AMED grants for emerging/re-emerging infectious disease drug development in consecutive fiscal years. Revenue is generated through a hybrid model: direct B2B sales of pharmaceuticals, IVDs, and medical devices to healthcare institutions; a multi-brand direct-to-consumer e-commerce footprint via the Well-Being OnlineShop and sub-brand storefronts (WellisAir, WithaPet, Pippo); and physical distribution through its newly established Korea (August 2024) and Vietnam (May 2025) branches, primarily serving healthcare professionals, medical institutions, veterinary clinics, pet owners, and consumer wellness buyers across Japan, South Korea, and Vietnam.

Japan Biotechno Pharma firmographics

Firmographics
Name
Japan Biotechno Pharma
Legal name
日本バイオテクノファーマ株式会社 (Japan Biotechno Pharma Co., Ltd.)
Website
https://japanbiotechnopharma.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Japan Biotechno Pharma is a Tokyo-based pharmaceutical and medical device company manufacturing antivirals, in vitro diagnostics, and animal health products, serving healthcare institutions, veterinary clinics, and consumers across Japan, Korea, and Vietnam.
Ownership category
akta.pro rank

Japan Biotechno Pharma industry classification

Industry
Product category
Pharmaceuticals and Medical Devices
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413), Surgical and Medical Instrument Manufacturing (339112)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
SECONDARYHLAMAFAI
Laboratory & Point-of-Care Diagnostic Devices (Analyzers, Test Kits, Microscopy)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Medical Devices & Supplies

Keywords

  • Pharmaceutical manufacturing
  • Biopharmaceutical development
  • Medical device manufacturing
  • In vitro diagnostics
  • Veterinary medical devices

Where Japan Biotechno Pharma is headquartered

Location

Headquarters

HQ city
Tokyo
HQ country
Japan
HQ region
Asia

Offices3 records

Markets served

Japan Biotechno Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Products: Revenue from antiviral drugs, antibody pharmaceuticals, vaccines/globulins, and approved treatments including Tepoxxx Capsule for poxviruses
  2. Medical Devices: Surgical instruments, infection prevention glasses (face shields), and related medical equipment
  3. In Vitro Diagnostics: J-Bio rapid PCR kits and other diagnostic pharmaceutical products
  4. Animal Health Products: AI digital stethoscopes, pet urine test kits, and animal health monitoring devices
  5. Well-Being Consumer Products: WellisAir air purification systems and consumer wellness products sold through online shop

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

Japan Biotechno Pharma product offering

Product offering

Core offering

Japan Biotechno Pharma manufactures and distributes pharmaceutical products (antiviral drugs including Japan's first approved Tecovirimat treatment for poxvirus complications, antibody drugs, vaccines, and globulins), medical devices (surgical instruments, infection protection eyewear, face shields, and the WellisAir air purification system), in vitro diagnostics (J-Bio Rapid PCR Kit for SARS-CoV-2, COVID-19 antibody/antigen test kits), and animal health products (AI-powered digital stethoscope and pet urine test kits). The company serves medical professionals, healthcare institutions, veterinary clinics, and individual consumers through its own e-commerce storefront and direct sales.

Product overview

Japan Biotechno Pharma operates as a diversified pharmaceutical and medical technology company with three main business segments: (1) Pharmaceutical Business covering antiviral drugs (Tepoxxx Capsule 200mg/Tecovirimat - Japan's first treatment for poxvirus complications), antibody drugs, and vaccines/globulins; (2) Medical Device Business including surgical instruments, infection control products (Shield Frame glasses, face shields), and WellisAir air purification system proven effective against influenza A virus and coronavirus; and (3) In Vitro Diagnostics and Animal Health Products including J-Bio Rapid PCR Kit for SARS-CoV-2, COVID-19 antibody/antigen test kits, iSWAB microbiome specimen collection tubes, AI-powered WITHaPET digital stethoscope, and PIPPO pet urine test kit. The portfolio spans human and veterinary applications with both pharmaceutical and medical device products.

Differentiator

Problem solved

Functional benefit

Brands

  • WellisAir: Air purification system for sterilization and air quality improvement.
  • J-Bio
  • WITHaPET
  • PIPPO
  • Tepox

Products and services

  • Tepoxxx Capsule 200mg (Tecovirimat) Antiviral capsule drug containing Tecovirimat 200mg, indicated for treatment of poxvirus infections including smallpox, mpox, cowpox, and post-vaccination complications. Approved as Japan's first such treatment for healthcare professionals and medical institutions.
  • WellisAir Air Purification System Air sterilization and purification device confirmed to reduce infectivity of influenza A virus (H3N2) and coronavirus. Sold to consumers and businesses seeking infection prevention through air quality control.
  • WITHaPET Digital Stethoscope AI-powered digital stethoscope designed for veterinary professionals and pet owners to monitor pet health through digital auscultation.
  • PIPPO Pet Urine Test Kit At-home urine testing kit for pets, enabling pet owners to perform preliminary health screening for their animals.
  • J-Bio Rapid PCR Kit SARS-CoV-2 In vitro diagnostic reagent enabling rapid PCR detection of SARS-CoV-2 for clinical laboratories and healthcare facilities, with regulatory approval (approval number 30300EZX00073000).
  • COVID-19 Antibody Test Kit (IgM/IgG) Rapid detection test kit for IgM and IgG antibodies to SARS-CoV-2, designed for healthcare professionals and diagnostic use to assess immune response following infection.
  • COVID-19 Antigen Test Kit Antigen detection test kit for identifying active SARS-CoV-2 infection, validated for the Omicron variant, sold as 2-test individual packaging.
  • Shield Frame Infection Protection Glasses Droplet protection eyewear developed for medical professionals to prevent infection during clinical work.
  • Face Shield Japanese-made face shield for droplet prevention, emphasizing comfort and performance for infection control in medical and workplace settings.
  • iSWAB Microbiome EL Specimen collection and transport tube enabling RNA extraction in 5 minutes for microbiome analysis, used by research and clinical laboratories.
  • Antibody Drugs Biopharmaceutical antibody drugs for therapeutic applications, developed and distributed for healthcare institutions.
  • Vaccines and Globulins Vaccine and immunoglobulin (globulin) products for immunization and passive immunity, distributed to medical institutions and healthcare providers.
  • Surgical Instruments and Equipment Medical devices and surgical instruments for healthcare facilities, distributed under the company's Class 1 medical device manufacturing and sales license.

Quantifiable outcome

  • Japan's first approved poxvirus treatment (Tepoxxx Capsule 200mg) - approved January 7, 2025
  • +2 more outcomes

Companies that use Japan Biotechno Pharma

Customer profile

Segments4 records

Ideal customer profiles3 records

Japan Biotechno Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Japan Biotechno Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Japan Agency for Medical Research and Development (AMED)coreStrategic or Co-development Partner · 1 February 2021Japan Biotechno Pharma was selected for AMED's programs for emerging and re-emerging infectious disease drug development in both Reiwa 3 (2021) and Reiwa 4 (2022) fiscal years, receiving government support for innovative pharmaceutical development targeting infectious diseases.

Scale indicators3 records

Recent moves10 records

Expansion highlights7 records

Japan Biotechno Pharma competitors and assessment

Company assessment

Direct peers

  • Chimerix: Chimerix develops antivirals targeting poxviruses and other infectious diseases. Comparable to Japan Biotechno Pharma as a small-cap antiviral developer with regulatory expertise in the same disease space as Tepoxxx.
  • Bavarian Nordic: Bavarian Nordic develops vaccines and therapeutics against poxviruses including mpox/smallpox (JYNNEOS vaccine). Comparable as a player in the broader poxvirus preparedness ecosystem, often used alongside Tecovirimat treatment.
  • SIGA Technologies: SIGA Technologies is the originator of Tecovirimat (TPOXX), the same active ingredient Japan Biotechno Pharma now sells in Japan under the Tepoxxx brand. Both companies operate in the poxvirus antiviral space and pursue government stockpiling channels.

Broad incumbents

  • FUJIFILM Holdings: FUJIFILM's healthcare segment includes pharmaceuticals, medical devices, and IVD reagents. Comparable as a diversified Japanese healthcare conglomerate with overlapping product categories across therapeutics, devices, and diagnostics.
  • Denka Company Limited: Denka is a Japanese chemical and specialty manufacturer with a healthcare segment that includes in vitro diagnostics and infection prevention products. Comparable as a Japanese company with overlapping diagnostic and medical device offerings.
  • H.U. Group Holdings (formerly SRL): H.U. Group operates clinical laboratory testing services and IVD products in Japan. Comparable as a Japanese diagnostics player with relevant IVD distribution and laboratory services overlap.
  • Sysmex Corporation: Sysmex is a leading Japanese in vitro diagnostics company with global reach. Comparable as a Japan-based IVD player, though much larger; useful for IVD regulatory and commercial benchmarking relevant to J-Bio PCR Kit.
  • Shionogi & Co., Ltd. Shionogi is a Japanese pharmaceutical company with a strong infectious disease and antiviral portfolio (including COVID-19 therapeutics). Comparable as a Japan-based pharma with regulatory expertise and government relationships in infectious disease drug development.
  • KM Biologics: KM Biologics is a Japanese vaccine and biologics manufacturer owned by Meiji Holdings. Comparable as a domestic Japanese player with biopharmaceutical manufacturing capabilities, vaccine portfolio, and regulatory licenses aligned with Japan Biotechno Pharma's pharmaceutical business.

Emerging players

  • AnGes MG: AnGes is a Japanese biotech focused on DNA vaccines and genetic medicines, with COVID-19 vaccine development history. Comparable as a small-cap Japanese biopharmaceutical with infectious disease R&D focus and government grant funding experience.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Japan Biotechno Pharma compliance and trust

Trust signal

Compliance4 records

Japan Biotechno Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Japan Biotechno Pharma leadership team

Management profile

Number of profiles

Profiles1 record

Japan Biotechno Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Japan Biotechno Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Japan Biotechno Pharma

What does Japan Biotechno Pharma do?

Japan Biotechno Pharma manufactures and distributes pharmaceutical products (antiviral drugs including Japan's first approved Tecovirimat treatment for poxvirus complications, antibody drugs, vaccines, and globulins), medical devices (surgical instruments, infection protection eyewear, face shields, and the WellisAir air purification system), in vitro diagnostics (J-Bio Rapid PCR Kit for SARS-CoV-2, COVID-19 antibody/antigen test kits), and animal health products (AI-powered digital stethoscope and pet urine test kits). The company serves medical professionals, healthcare institutions, veterinary clinics, and individual consumers through its own e-commerce storefront and direct sales.

Is Japan Biotechno Pharma a public or private company?

Japan Biotechno Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Japan Biotechno Pharma founded?

Japan Biotechno Pharma was founded in 2016. It employs 11 to 50 people.

Where is Japan Biotechno Pharma based?

Japan Biotechno Pharma is headquartered in Tokyo, Japan, in the Asia region.

How does Japan Biotechno Pharma make money?

Five revenue lines are on record. Pharmaceutical Products are the primary driver. The others are medical Devices, in Vitro Diagnostics, animal Health Products and well-Being Consumer Products.

Who are Japan Biotechno Pharma's main competitors?

Direct peers on record are Chimerix, Bavarian Nordic and SIGA Technologies. Broad incumbents are FUJIFILM Holdings, Denka Company Limited, H.U. Group Holdings (formerly SRL), Sysmex Corporation, Shionogi & Co., Ltd. and KM Biologics. AnGes MG is listed as an emerging player.

Does Japan Biotechno Pharma have an API?

No public API is recorded for Japan Biotechno Pharma.

What industry is Japan Biotechno Pharma in?

Japan Biotechno Pharma's product category is Pharmaceuticals and Medical Devices. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals